Atrasentan
AssetAlso called atrasentan hydrochloride, CHK-01, ABT-627, Vanrafia
Blocks endothelin A receptor signaling involved in tumor growth and survival.
- Stage
- Approved
- Modality
- Small molecule
- Target
- EDNRA
- 18
- Indications
- 18
- Trials
- 4
- Developers
Approved by the FDA on Apr 2, 2025 (NDA219208). FDA
Indications
18IgA nephropathy
Approved, koreabiomed.com
Primary immunoglobulin a nephropathy
Approved, FDA
Primary IgA nephropathy
Approved, hitnews.co.kr
15 more
In the full profile
- Target and mechanism1
- Owner and partners4
- Trials18
- Evidence for its targets2
- Competitors12
- Signals12
Every asset’s record: target, stage, trials and the evidence behind it.